Pharmesis International Ltd
Company Profile
- Business description- Pharmesis International Ltd is an investment holding company. The company manufactures pharmaceutical products in the form of tablets, granules, pills, and other forms. Its operating segments are Western drugs, which are chemically formulated drugs and are marketed under the Kinna brand; TCM-formulated drugs, which refer to Traditional Chinese Medicine and are marketed under the Longlife brand; and Distribution, which refers to agency products and internally manufactured products which are marketed through the distribution arm. The company derives revenue from the sale of medicines to domestic customers in China. 
- Contact- 5 Kallang Sector 
 No. 03-02
 Singapore349279
 SGP- T: +65 68460766 
- Sector- Healthcare - Stock type- Defensive 
- Industry- Drug Manufacturers - Specialty & Generic - Fiscal Year End- 31 December 2025 - Employees
Stocks News & Analysis
stocks
Microsoft earnings: Strong, including Azure, but overall guidance is in line
stocks
After earnings, is Tesla stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
| Index | Last price | Change | % Change | 
|---|---|---|---|
| All Ordinaries | 9,178.00 | 28.70 | -0.31% | 
| CAC 40 | 8,121.07 | 36.22 | -0.44% | 
| DAX 40 | 23,958.30 | 160.59 | -0.67% | 
| Dow JONES (US) | 47,592.27 | 70.15 | 0.15% | 
| FTSE 100 | 9,717.25 | 42.81 | -0.44% | 
| HKSE | 25,906.65 | 376.04 | -1.43% | 
| NASDAQ | 23,741.18 | 160.03 | 0.68% | 
| Nikkei 225 | 52,411.34 | 1,085.73 | 2.12% | 
| NZX 50 Index | 13,548.32 | 89.03 | 0.66% | 
| S&P 500 | 6,846.68 | 24.34 | 0.36% | 
| S&P/ASX 200 | 8,881.90 | 31.30 | -0.35% | 
| SSE Composite Index | 3,954.79 | 32.11 | -0.81% |